-

05:06:41 AM

EDIT Stock News

EDIT - Editas Medicine Inc

11/17/22 7:15 AM

Nasdaq : EDIT

clinical trialhigh short

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of consistent improvement in BCVA plus additional efficacy endpoints seen in homozygous patients Achieved proof of concept and identified a responder population In view of the small population, the

RHEA-AI

neutral

11/02/22 6:30 AM

Nasdaq : EDIT

high short

Editas Medicine Announces Third Quarter 2022 Results and Business Updates

Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease On track to announce initial preliminary clinical data from RUBY trial by year-end Completed cell editing and currently scheduling first patient dosing with EDIT-301 in Phase 1/2 EDITHAL trial for TDT Company to

RHEA-AI

neutral

10/26/22 6:30 AM

Nasdaq : EDIT

conferenceshigh short

Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 2, 2022, at 8:00 a.m. ET to provide a corporate update and results for the

RHEA-AI

neutral

10/13/22 6:00 AM

Nasdaq : EDIT

clinical trialhigh short

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach Treated eyes showed morphological and functional photoreceptor preservation EDIT-103 advancing towards IND-enabling

RHEA-AI

neutral

09/01/22 6:30 AM

Nasdaq : EDIT

conferenceshigh short

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference Format: Fireside Chat Date:

RHEA-AI

neutral

08/03/22 6:29 AM

Nasdaq : EDIT

high short

Editas Medicine Announces Second Quarter 2022 Results and Business Updates

Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team Achieved successful engraftment of first patient treated with EDIT-301 for sickle cell disease; first clinical use of Editas-engineered AsCas12a enzyme FDA removed partial clinical hold for RUBY trial of

RHEA-AI

very positive

07/27/22 6:30 AM

Nasdaq : EDIT

high short

Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301 First clinical use of Editas-engineered AsCas12a enzyme Initial clinical data from the RUBY trial expected by year-end CAMBRIDGE, Mass., July 27,

RHEA-AI

positive

07/26/22 6:26 AM

Nasdaq : EDIT

conferenceshigh short

Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 3, 2022, at 8:00 a.m. ET to provide financial results and corporate updates for the

RHEA-AI

neutral

07/20/22 4:30 PM

Nasdaq : EDIT

high short

Editas Medicine Reports Inducement Grant to New Chief Medical Officer

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Baisong Mei, M.D., Ph.D. In connection with Dr. Mei’s appointment,

RHEA-AI

very positive

07/18/22 7:00 AM

Nasdaq : EDIT

managementhigh short

Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Company’s Senior Vice President and Chief Medical Officer, effective immediately. Dr. Mei will lead

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 Next

EDIT Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.editasmedicine.com
CeoCynthia Collins
Security nameEditas Medicine Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees235
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address11 Hurley St
StateMassachusetts
CityCambridge
Zip02141-2110
CountryUS
Phone16174019000

About Editas Medicine Inc

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.